Sernova (TSE:SVA) has released an update.
Sernova Corp., a clinical-stage biotech firm, has announced an oversubscribed private placement of $4.7M, surpassing its $4M goal, with the final closing set for September 3, 2024. The company specializes in cell therapy technologies for chronic diseases with its flagship Cell Pouch System, aiming to create a ‘functional cure’ for insulin-dependent diabetes.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
